secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001493152-24-004933
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma suspends at-the-market equity offering under Sales Agreement with ThinkEquity
--------------------------------------------------------------------------------

- Suspended prospectus supplement dated July 14, 2023; no sales of common stock until new filing.
- Sales Agreement with ThinkEquity LLC remains in full force and effect.
- No reason given for suspension; company may resume after filing new supplement.
- Suspension removes immediate dilution risk but pauses potential capital raising.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315224004933/0001493152-24-004933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315224004933/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-004933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer